Recent Developments in Preclinical DNA Vaccination

Vaccines

Kenji Okuda¹  Yoshiyuki Wada² 

[1] Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan; E-Mail:;Vaccine Institute, Yokohama, Kanagawa Prefecture 2235-0045, Japan; E-Mail:

关键词: DNA vaccine;    genetic adjuvants;    electroporation;   

DOI  :  10.3390/vaccines2010089

来源: mdpi

【 摘 要 】

The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.